HCAR2 and systemic lupus erythematosus: These findings provide compelling evidence supporting the potential of targeting microglial GPR109A as a potent strategy for reversing spinal neuroinflammation, correcting abnormal excitatory synaptic activity, and managing chronic pain induced by SLE [26].